Evropská unie - čeština - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, typ 2 - léky užívané při diabetu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. trojkombinační léčbě) jako doplněk k dietním opatřením a cvičení u pacientů nedostatečně maximální tolerované dávky metforminu a sulfonylmočoviny. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Evropská unie - čeština - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, typ 2 - léky užívané při diabetu - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 a 5. 1 pro dostupné údaje o různých kombinacích).

Evropská unie - čeština - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, typ 2 - léky užívané při diabetu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. trojkombinační léčbě) jako doplněk k dietním opatřením a cvičení u pacientů nedostatečně maximální tolerované dávky metforminu a sulfonylmočoviny. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Evropská unie - čeština - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - hydrochlorid doxorubicinu - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastická činidla - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Evropská unie - čeština - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin hydrochloridu - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 a 5. 1 pro dostupné údaje o různých kombinacích).

Evropská unie - čeština - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, typ 2 - léky užívané při diabetu - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. trojkombinační léčbě) jako doplněk k dietním opatřením a cvičení u pacientů nedostatečně maximální tolerované dávky metforminu a sulfonylmočoviny. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Evropská unie - čeština - EMA (European Medicines Agency)

teva b.v. - hydrochlorid doxorubicinu - neoplasmy prsů - antineoplastická činidla - myocet lipozomální, v kombinaci s cyklofosfamidem je indikován k první linii léčby metastatického karcinomu prsu u dospělých žen.

Evropská unie - čeština - EMA (European Medicines Agency)

baxter holding b.v. - hydrochlorid doxorubicinu - sarcoma, kaposi; multiple myeloma; ovarian neoplasms; breast neoplasms - antineoplastická činidla - caelyx pegylovaný lipozomální je indikován:jako monoterapie u pacientů s metastazujícím karcinomem prsu, kde je zvýšené riziko srdeční;pro léčbu pokročilého karcinomu vaječníků u žen, které selhaly v první linii chemoterapií na bázi platiny režim;v kombinaci s přípravkem bortezomib pro léčbu pacientů s progresivním mnohočetným myelomem, kteří absolvovali alespoň jednu předchozí léčbu a kteří již podstoupili nebo jsou nevhodné pro transplantaci kostní dřeně;pro léčbu aids-související kaposiho sarkomu (ks) u pacientů s nízkým počtem cd4 (.

Evropská unie - čeština - EMA (European Medicines Agency)

genzyme europe bv - sevelamer hydrochloridu - hyperphosphatemia; renal dialysis - všechny ostatní terapeutické přípravky - tasermity je indikován k léčbě hyperfosfatemie u dospělých pacientů podstupujících hemodialýzu nebo peritoneální dialýzu. sevelamer-hydrochloridem by měly používat v rámci komplexního léčebného přístupu, který by mohl zahrnovat doplňky vápníku, 1,25 dihydroxyvitamin vitamin d3 nebo jeden z jeho analogy řídit rozvoj renální kostní choroby.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

ardeapharma, a.s., Ševětín array - 2972 arginin-hydrochlorid - koncentrát pro infuzní roztok - 21% - arginin-hydrochlorid